Plus Therapeutics Relocates Principal Executive Offices
Ticker: PSTV · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $35 million, $2.5 million, $1.00 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: office-relocation, administrative
TL;DR
PLUS THERAPEUTICS moved its HQ to Houston, TX on 8/26/25.
AI Summary
On August 26, 2025, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2710 Reed Road, Suite 160, Houston, Texas 77051. This move is effective as of August 26, 2025.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments within the company.
Risk Assessment
Risk Level: low — This filing is a routine administrative update regarding the company's office location and does not involve significant financial or operational changes.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- August 26, 2025 (date) — Effective date of office change
- 2710 Reed Road, Suite 160, Houston, Texas 77051 (location) — New principal executive offices
FAQ
What is the new address for PLUS THERAPEUTICS, INC.'s principal executive offices?
The new address is 2710 Reed Road, Suite 160, Houston, Texas 77051.
When did the change in principal executive offices become effective?
The change became effective on August 26, 2025.
What was the previous location of the principal executive offices?
The filing does not explicitly state the previous address, only that there has been a change.
Is this a significant operational change for PLUS THERAPEUTICS, INC.?
The filing describes this as a change in principal executive offices, which is typically an administrative update rather than a major operational shift.
What is the company's ticker symbol?
The filing does not explicitly state the ticker symbol, but the context suggests it is related to PLUS THERAPEUTICS, INC.
Filing Stats: 1,101 words · 4 min read · ~4 pages · Grade level 13 · Accepted 2025-08-26 06:30:40
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 PSTV The Nasdaq Capital Market Ind
- $35 million — value of listed securities of at least $35 million (the "MVLS Standard"), as well as compl
- $2.5 million — intain stockholders' equity of at least $2.5 million (the "Equity Standard"). Accordingly, t
- $1.00 b — ce period to regain compliance with the $1.00 bid price rule under Nasdaq Listing Rule
Filing Documents
- d919644d8k.htm (8-K) — 27KB
- 0001193125-25-188075.txt ( ) — 140KB
- pstv-20250826.xsd (EX-101.SCH) — 3KB
- pstv-20250826_lab.xml (EX-101.LAB) — 18KB
- pstv-20250826_pre.xml (EX-101.PRE) — 11KB
- d919644d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Form 8-K contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding the proposed timing of any reverse stock split and the Company's ability to maintain compliance with Nasdaq's continued listing rules. All statements in this Form 8-K other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "expect," "will," "potential," "anticipating," "planning," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this Form 8-K could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the price and volatility of the Company's common stock; the Company's liquidity and capital resources and its ability to raise additional cash; market conditions, product performance, litigation or potential litigation; and, competition within the cancer diagnostics and therapeutics field. This list of risks, uncertainties, and other factors is not complete. The Company discusses some of these matters more fully, as well as certain risk factors that could affect the Company's business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. Any or all forward-looking statements the Company makes may turn out to be wrong and can be affected by inaccurate
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 26, 2025 PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer